Business columnist Gene Marcial discusses potential for MuGard

October 2, 2009

Renowned business columnist and author Gene Marcial listed Access Pharmaceuticals, Inc. (OTCBB: ACCP) as one of three promising companies to watch in his latest Inside Wall Street column.

The article states:

“As major pharmaceuticals seek companies with a pipeline of promising drugs to augment their own depleting inventories, some pros bet that one target will be Access Pharmaceuticals (ACCP), now at 2.85 a share. It hit a high of 17 in 2005. Its drug MuGard, approved by the FDA in 2007, treats oral mucositis, a debilitating side effect of chemotherapy and radiation treatment. It’s now sold in Europe, with a global market potential of $5 billion, says Access. The company regained North American rights this summer and hopes to partner with a big drugmaker. Keith Markey of Griffin Securities (it did business with Access) says MuGard alone is worth more than Access’ stock, and its two cancer drugs, Prolindac and Thiarabine, are big extras that “make Access a cheap takeover bait.” Robert Wasserman of Dawson James Securities says Access is an enticing target worth 11.”

This marks the third time Access has been mentioned in Marcial’s column since 2007.  The Company was previously included  in  July 2008 and September 2007.

Access was also mentioned in  ‘Gene Marcial’s 7 Commandments of Stock Investing’ as one of three, unrecognized attractive biotech companies that are not widely followed by Wall Street, but “whose prospects look tantalizing because of their huge potential value.”

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access’ products include ProLindac™, currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard™ for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin™-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix®, a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This article contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for ProLindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access’ plans to continue and initiate clinical trials, the value of its products in the market (including MuGard and the size of the overall market for mucositis products), its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access’ need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access’ Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.